SCHEMBL2069436

SCHEMBL2069436

CCOc1ccc(-n2cnc3cc(NCc4ccc(CC)cc4)cnc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.54
KDM4E B2RXH2 6/20 0.54
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
GAA P10253 5/20 0.53
HSD17B10 Q99714 2/20 0.50
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 2/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
ALOX15 P16050 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
APP P05067 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15799974 0.90 GAA (0.45) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL2067541 0.87 NPC1 (0.45) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL15201646 0.85 MAPT (0.56) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL770102 0.83 MAPT (0.70) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL15213067 0.83 MAPT (0.47) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL2069816 0.82 MAPT (0.43) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL15213085 0.82 MEN1 (0.41) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL2069427 0.82 MAPT (0.47) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL15213129 0.81 MEN1 (0.40) MAPTALDH1A1HPGDGAANPC1
SCHEMBL783977 0.81 MAPT (0.52) MAPTKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754082-B2 Antiviral drugs for treatment of Arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-06-17 US claimed
US-20140128426-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2014-05-08 US claimed
EP-2182805-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC (US) 2013-06-26 EP claimed
US-8461177-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2013-06-11 US claimed
US-20110064693-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES, INC. 2011-03-17 US claimed
EP-2182805-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2010-05-12 EP claimed
WO-2009029622-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-03-05 WO claimed
US-9096597-B2 Antiviral drugs for treatment of Arenavirus infection Kineta Four, LLC (US) 2015-08-04 US disclosed
US-9096597-B2 Antiviral drugs for treatment of Arenavirus infection Kineta Four, LLC (US) 2015-08-04 US disclosed
US-9096597-B2 Antiviral drugs for treatment of Arenavirus infection Kineta Four, LLC (US) 2015-08-04 US disclosed
US-20140243367-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2014-08-28 US disclosed
US-20140243367-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2014-08-28 US disclosed
US-20140243367-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2014-08-28 US disclosed
US-8461177-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2013-06-11 US disclosed
US-8461177-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2013-06-11 US disclosed
US-20110064693-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES, INC. 2011-03-17 US disclosed
US-20110064693-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES, INC. 2011-03-17 US disclosed
US-20110064693-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES, INC. 2011-03-17 US disclosed
EP-2182805-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2010-05-12 EP disclosed
WO-2009029622-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064693-A1 Antiviral Drugs for Treatment of Arenavirus Infection EIF2AK2, ZC3HAV1, SARS1 MAPT 4118/4885KDM4E 4051/4885ALDH1A1 2286/4885
US-20140128426-A1 Antiviral Drugs for Treatment of Arenavirus Infection EIF2AK2, ZC3HAV1, SARS1 MAPT 4118/4885KDM4E 4051/4885ALDH1A1 2286/4885
US-20140243367-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION EIF2AK2, ZC3HAV1, SARS1 MAPT 4118/4885KDM4E 4051/4885ALDH1A1 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.